Volume 95 Issue 8 | p. 15 | Concentrates
Issue Date: February 20, 2017

Boehringer, Cornell target the lung

Department: Business
Keywords: drug discovery, COPD, Boehringer Ingelheim

Boehringer Ingelheim and Weill Cornell Medicine are joining to discover new approaches to treating chronic obstructive pulmonary disease. The three-year collaboration is intended to combine Weill Cornell’s understanding of chronic airway diseases with Boehringer’s expertise in discovering therapies for respiratory disease. The two organizations earlier collaborated on inflammatory bowel disease.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment